Eli Lilly says Kisunla demonstrated ‘meaningful results’ for people showing early symptoms of the disease
Federal health authorities on Tuesday gave approval to an experimental new drug that has shown to delay the onset of Alzheimer’s disease in trials.
Donanemab, manufactured by Eli Lilly, is the second medication that has won the blessing of the Food and Drug Administration (FDA) to treat patients showing early symptoms of the disease, most prominently cognitive impairment.
More Stories
Researchers create AI-based tool that restores age-damaged artworks in hours
Australia has ‘no alternative’ but to embrace AI and seek to be a world leader in the field, industry and science minister says
European journalists targeted with Paragon Solutions spyware, say researchers